Quantcast
Last updated on April 20, 2014 at 7:48 EDT

Latest Methylphenidate Stories

2009-11-16 08:00:00

PHILADELPHIA, Nov. 16 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced new study results on INTUNIV(TM) (guanfacine) Extended-Release Tablets published in the October Journal of Child and Adolescent Psychopharmacology. In this open-label safety study, there was no evidence of unique adverse effects with the combination of INTUNIV and amphetamine or methylphenidate relative to what was observed with either medication...

2009-11-04 11:00:00

LAS VEGAS, Nov. 4 /PRNewswire/ -- New findings presented today show that CONCERTA® (OROS® methylphenidate HCl Extended-Release Tablets CII) is the only stimulant medication with data that demonstrate a significant treatment effect on attention at one hour and through 12.5 hours in children with Attention Deficit Hyperactivity Disorder (ADHD). ADHD is a common and treatable medical condition characterized by inattention, hyperactivity and impulsivity(1)...

2009-10-30 14:00:00

HONOLULU, Oct. 30 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced findings at a major medical meeting from a Phase IIIb study of the tolerability and effectiveness of Daytrana® (methylphenidate transdermal system) in adolescents aged 13 to 17 years diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD). In addition, data regarding the pharmacokinetic profile of Daytrana in children...

2009-10-29 23:29:52

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention-Deficit/Hyperactivity Disorder (ADHD) treatments, INTUNIVâ“ž¢ (guanfacine) Extended Release Tablets, Vyvanse® (lisdexamfetamine dimesylate) Capsules CII, and Daytrana® (methylphenidate transdermal system) CII, at a national meeting of psychiatrists to be held October 27 -...

2009-10-29 13:07:00

HONOLULU, Oct. 29 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention-Deficit/Hyperactivity Disorder (ADHD) treatments, INTUNIV(TM) (guanfacine) Extended Release Tablets, Vyvanse®( ) (lisdexamfetamine dimesylate) Capsules CII, and Daytrana®( ) (methylphenidate transdermal system) CII, at a national meeting of psychiatrists...

2009-09-09 07:00:00

TITUSVILLE, N.J., Sept. 9 /PRNewswire/ -- Attention Deficit Hyperactivity Disorder (ADHD) is estimated to impact up to 20 percent of children(1) and 4 percent of adults in the U.S.(2) Recent studies suggest ADHD is underdiagnosed: researchers estimate up to 20 percent of U.S. school-aged children meet the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria, but only 7.8 percent report receiving an ADHD diagnosis.(3) Meanwhile, it is estimated that just 15 percent of...

2009-07-08 17:00:00

Consumers Could Save Roughly $3,000 A Year By Switching From Expensive Brand Name Drugs to Equally Effective Generics To Treat Attention Deficit Hyperactivity Disorder (ADHD) YONKERS, N.Y., July 8 /PRNewswire-USNewswire/ -- According to a new Consumer Reports Best Buy Drugs report, parents should be skeptical if their doctors offer them free prescription drug samples, especially for the treatment of attention deficit hyperactivity disorder (ADHD). Free samples can hook consumers on...

0b861aca1779ac6b25fd8b8ab9aaba0e1
2009-06-19 11:36:11

A UK ethicist suggests that healthy people should be able to take the anti-hyperactivity drug Ritalin to boost brainpower, BBC News reported. If the drug is safe for children, adults should also be able to take it, according to Bioethics expert Professor John Harris of the University of Manchester. Harris wrote on the British Medical Journal website that many students were already using the drug, which in the UK requires a prescription. However, an expert in the U.S. said there were too many...

0d39cf1dae95bad33b4076507742bf311
2009-06-16 06:00:00

New evidence from a government-backed study suggests that attention deficit drugs like Ritalin and Adderall can increase the risk of sudden death, yet federal health regulators continue to urge parents to keep their children on the medications. The study, which appears in the American Journal of Psychiatry, suggests that the stimulant drugs used to treat attention deficit and hyperactivity disorder may be linked to sudden death in children and adolescents. Drugs like Ritalin and Adderall...

2009-05-28 11:15:43

A Canadian researcher working in the U.K. says doctors, authors and educators are doing hyperactive children a disservice by claiming that hyperactivity as we understand it today has always existed.Matthew Smith says not only is that notion wrong, it misleads patients, their parents and their physicians. Smith, who is from Edmonton, is finishing up his PhD at the Centre for Medical History at the University of Exeter.Hyperactivity disorder, or ADHD, is currently the most commonly diagnosed...